Effect of interferon on blood lipids

Clinical Drug Investigation

Volumn 11, Issue 1, 1996, Pages 43-48

  Malaguarnera, Mariano ^a,b   Giugno, Ignazio ^a   Ruello, Pasqualina ^a   Pistone, Giovanni ^a   Restuccia, Salvatore ^a   Trovato, Barbara Adriana ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; CHOLESTEROL; HEPATITIS C ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACCURACY; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC ACTIVE HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; PRIORITY JOURNAL; SINUS TACHYCARDIA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030032053     PISSN: 01142402     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199611010-00005     Document Type: Article

References (30)

1. Kirchner H. The Interferon system as an integral part of the defence system against infections. Antiviral Res 1986; 6: 1-7
2. Mariano TM, Donnelly RJ, Soh J, et al. Structure and function of the type I interferon receptor. In: Baron S, Coppenhaver DH, Dianzani F, et al, editors. Interferon principles and medical applications. Galveston, Texas: The University of Texas Medical Branch Publ., 1992: 129-38
3. Stuber D, Fountoulakis M, Garotta G. IFN gamma receptor: protein structure and function. In: Baron S, Coppenhaver DH, Dianzani F, editors. Interferon principles and medical applications. Galveston, Texas: The University of Texas Medical Branch Publ, 1992: 139-50
4. Sen GC, Ransohoff RM. Interferon-induced antiviral actions and their regulation. Adv Virus Res 1993; 42: 57-61
5. Tamm I, Lin SL, Pfeffer LM, et al. Interferons alpha and beta as cellular regulatory molecules. In: Gresser I, editor. Interferon 9. London: Academic Press, 1987: 13-74
6. Reiter Z. Interferon - a major regulator of natural killer cell-mediated cytotoxicity. J Interferon Res 1993; 13: 247-8
7. Verhagen A, Mackay IR, Rowely M, et al. Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes. Nat Immun Cell Growth Regul 1990; 9: 325-8
8. Adams DO. Regulation of macrophage function by interferon gamma. In: Baron S, Coppenhaver DH, Dianzani F, et al., editors. Interferon principles and medical applications. Galveston, Texas: The University of Texas Medical Branch Publ, 1992: 341-51
9. Malaguarnera M, Giugno I, Ruello P, et al. Lp(a), cardiomiopatia e intcrferone. Abstract Book of 8° Congresso Nazionale della Società Italiana Per Lo Studio Dell'Arteriosclerosi. 1994 8-9 Dicembre; Roma, 55
10. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991; 99: 557-62
11. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med 1988; 85: 549-53
12. Deyton LR, Walker RE, Kovacs JA, et al. Reversible cardiac dysfunction associated with interferon alpha therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med 1989; 321: 1246-9
13. Spath-Schwable E, Porzsolt F, Digel W, et al. Elevated plasma cortisol levels during interferon-γ treatment. Immunopharmacology 1989; 17: 141-7
14. Hudes BK, Cheathan AK, Sanyal AJ, et al. Interferon causes elevation of serum triglycerides during the treatment of chronic hepatitis C. Digestive Disease Week and the 94th Annual Meeting of the American Gastroenterological Association. Gastroenterology 1993; 104 4 Suppl.: A 918
15. Malaguarnera M, Giugno I, Trovato BA, et al. Lipoprotein (a) concentration in patients with chronic active hepatitis C before and after interferon treatment. Clin Ther 1995; 17 (4): 721-9
16. Tribble DL, Krauss RM. HDL and coronary heart disease. Adv Int Med 1993; 38: 1-29
17. Zhuang YY, Wang JJ. Increased lipoprotein (a): an independent risk factor for cardiovascular and cerebrovascular disease. Clin Med J Engl 1993; 106 (8): 597-600
18. Giugno I, Ruello P, Trovato BA, et al. Lp(a) in subjects with active chronic hepatitis. 4th International Workshop on Lipid Metabolism: 1994 15-16 April: Dijon. Atherosclerosis 1994; 110 Suppl.: S101
19. Giugno I, Ruello P, Trovato BA, et al. Prognostic value of Lp(a) in cirrhosis of the liver. In: 4th International Workshop on Lipid Metabolism: 1994 15-16 April: Dijon. Atherosclerosis 1994; 110 Suppl.: S101
20. Memon RA, Freingold VR, Moser AN, et al. In vivo effects of interferon-alpha and interferon-gamma on lipolysis and ketogenesis. Endocrinology 1992; 131 (4): 1695-702
21. Beutler BA, Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 1985; 135: 3969-71
22. Saxena U, Witte LD, Goldberg IJ. Tumor necrosis factor induced release of endothelial cell lipoprolein lipase. Arteriosclerosis 1990; 10: 470-3
23. Patton JS, Shepard M, Wilking H, et al. Interferons and tumor necrosis factor have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci USA 1986; 83; 8313-7
24. Gotto AM, Gorry GA, Thompson JR, et al. Relationship between plasma lipid concentrations and coronary artery disease in 496 patients. Circulation 1977; 56; 875-83
25. Holmes DR, Elveback LR, Frye RL, et al. Association of risk factor variables and coronary artery disease documented with angiography. Circulation 1981; 63: 293-9
26. Brunner D, Altmann S, Loebel K, et al. Serum cholesterol and triglycerides in patients suffering from ischemic heart disease and in healthy subjects. Atherosclerosis 1977; 28 (2): 197-204
27. Carlson LA, Bottiger LE, Ahfeldt PE. Risk factors for myocardial infarction in the Stockholm Prospective Study: a 14-year follow up focussing on the role of plasma triglycerides and cholesterol. Acta Med Scand 1979; 206 (5): 351-60
28. Hulley SB, Rosemann RH, Bawal RD, et al. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart diseases. N Engl J Med 1990; 302: 1383-9
29. Bainton D, Miller NE, Bolton CH, et al. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. Br Heart J 1992; 68: 60-6
30. Assmann G, Shulte H. Triglycerides and atherosclerosis. Results from the Prospective Cardiovascular Münster Study. Atherosclerosis Rev 1991; 22: 51-7